Experiences with

Glecaprevir / Pibrentasvir

#HCV #Treatment #glecaprevir #pibrentasvir http://bit.ly/2kTBoLx

#HCV #Treatment #glecaprevir #pibrentasvir http://bit.ly/2kTBoLx

It has been weeks since AbbVie's New #Drug Application for glecaprevir/pibrentasvir. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9

It has been weeks since AbbVie's New #Drug Application for glecaprevir/pibrentasvir. At last, the #FDA replied and approved the new regimen. Click below for a recap of the application. #health #HCV #hepatitis http://bit.ly/2lczWF9

AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ

AbbVie has submitted a New Drug Application to the FDA for its investigational pan-genotypic regimen of glecaprevir/pibrentasvir for HCV. Eight studies have shown high SVR across all major genotypes in patients and other health conditions. http://bit.ly/2iBQ2CZ

After treatment with AbbVie’s new pangenotypic regimen of glecaprevir/pibrentasvir, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr

After treatment with AbbVie’s new pangenotypic regimen of glecaprevir/pibrentasvir, results have shown an average SVR rate of 97.5% across all HCV genotypes in only 8 weeks of therapy. http://bit.ly/2ggJHjr

A recent study has shown that 102 out of 104 HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe

A recent study has shown that 102 out of 104 #HCV patients w/ advanced chronic kidney liver disease (98%) have achieved SVR12 (#hepatitis C is undetectable for twelve or more weeks after the end of treatment) with no virological failures. This is an indication that there is hope for patients with severe